Back to Atlas
APotentially durableStandard research/education caution
CMP-0041
Approved/legacy cardiac drug; senolytic use not approved
Digitoxin
Senolytic / Cardiac glycoside
Senolytic screen candidate
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Cardiac glycoside
- Primary mechanism
- Na+/K+-ATPase inhibition
- Primary market use
- Cardiology / senolytic research
Pharmacology
- Molecular weight (Da)
- 764.94
- Oral bioavailability
- Oral; high
- Half-life
- ~5-7 d
- Route tags
- Route-dependent / verify
- Evidence level
- Approved/Preclinical
- Clinical status
- Approved/legacy cardiac drug; senolytic use not approved
- Value-for-money score
- 1 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Strong toxicity and interaction concerns overwhelm practical value